Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNK6106 vs Rifaximin in Hepatic Cirrhosis with HE History
NCT03712280Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ornithine phenylacetate in hepatic encephalopathy (HE) (4 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Ammonia Plasma Levels at Baseline and Day 5. Started Dec 2018; status: completed.
02
Drugs
ornithine phenylacetate
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT03712280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712280.